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Introduction
Bickerstaff's brainstem encephalitis (BBE) is a rare neurological disease characterized by acute ophthalmoplegia, ataxia, and altered sensorium. Almost all patients have a monophasic remitting course and generally a good outcome. 1 Its exact cause remains unknown, but it has been postulated that BBE has an autoimmunologic origin. Very often it follows preceding illness and an association with certain infections, including cytomegalovirus, campylobacter jejuni, typhoid fever and Mycoplasma pneumoniae, has been documented. [2] [3] [4] We describe a case of BBE with an aggressive clinical course, and an atypical remarkable spinal cord involvement at magnetic resonance imaging (MRI).
Case report
A 65-year-old woman was admitted to our institution in November 2013 because of fewer, headache, and vomiting. In her clinical history there were psychiatric disorders (hypochondria, generalized anxiety disorder, bipolar disorder); she had undergone anti-influenza vaccine 10 days before the onset of symptoms.
After admission, the patient quickly developed dysphagia, disturbed status of consciousness, progressive muscle weakness, with progression to tetraparesis and urinary retention. Blood tests showed a mild increase of inflammatory markers; however, laboratory data were negative for infectious agents. Cerebrospinal fluid (CSF) examination showed a marked hyperproteinorrachia, with total protein 1521 mg/dl (normal value: 150-400 mg/dl), and mild pleiocitosis (cell count 18 cells/ ml, normal <3). Oligoclonal bands were found in the CSF, but not in the serum, suggesting an intrathecal immunoglobulin production. Electroencephalogram (EEG) reported diffuse slowing without seizure waveforms.
MRI showed central nervous system (CNS) and peripheral nervous system (PNS) involvement, with T2hyperintense lesions in the brainstem and in the spinal cord ( Figures 1 and 2 ). After intravenous injection of gadolinium, both lesions showed T1 shortening, confirming blood-brain barrier breakdown. There was also evident gadolinium enhancement of the cauda equina ( Figure 3 ) and of the III, VII and VIII cranial nerves ( Figure 1 (d) , (e)). PNS involvement was validated by electromyography demonstrating marked muscle denervation in the lower limbs and decreased conduction velocity in the right arm.
Antibody screenings for autoimmune encephalitis (anti-N-methyl-D-aspartate (anti-NMDA), anti-leucine-rich glioma inactivated-1 (antiLGI1), anti-contactin-associated protein-like 2 (anti-CASPR2), anti-gamma-aminobutyric acid (anti-GABA) b1 and 2-r, anti-glutamate receptor (anti-GluR1) and R2) and for vasculitis were unremarkable. Anti-aquaporin4 antibodies were negative. Although specificity of anti-aquaporin4 reaches almost 100% in some studies, 5 the fact that anti-aquaporin4 antibodies were negative does not exclude the neuromyelitis optica diagnosis entirely, but does corroborate other entities. A diagnosis of uncommon BBE was suspected and antibodies to gangliosides were required, with anti-GM1 and anti-GD1b positivity. The patient received corticosteroid and gamma globulin by intravenous administration with improvement of consciousness. Within three months, she could manage to talk and swallow, and she had a total recovery of upper limb function; however, persistent paraparesis and neurological bladder were assessed. MRI at four-month-follow-up showed persistent spinal cord enhancement with progressive resolution of the lesions. She was discharged while receiving prednisone per os. At one-year-follow-up, the patient had persistent paraplegia with inability to walk unaided.
Discussion
BBE is a rare neurological condition with characteristic signs and symptoms, including altered sensorium. The definition of BBE has evolved since the original description by Bickerstaff and Cloake 6 because of the availability of new diagnostic tools, including MRI and anti-GQ1b antibody testing. Anti-Gq1b antibody seropositivity has suggested that BBE may be part of a spectrum of diseases known as anti-Gq1b antibody syndromes, including also Miller Fisher syndrome (MFS) and Guillain-Barre´syndrome (GBS). 7 There are a number of features shared by BBE and MFS, a variant of GBS, including prodromal infections, ophthalmoplegia, and albuminocytological dissociation in the CSF. The similarities between BBE, MFS and GBS may often cause confusion especially in the setting of clinical overlap. It has been reported that, in contrast to BBE, most cases of MFS show few if any signs of CNS involvement. 7 Therefore, patients are generally classified as having BBE rather than MFS if there is evidence of corticospinal tract abnormalities, a disturbed state of consciousness, or significant brainstem lesions on MRI or at autopsy. 8 According to the literature, T2high-signal lesions have been reported in the upper mesencephalon, cerebellum, thalamus or brainstem in patients with BBE. 9 In our case, the presence of anti-GM1 and anti-GD1b seropositivity, clinical features of central involvement (especially altered sensorium with Babinski sign), as well as the history of previous vaccine and MRI abnormalities in the brainstem, indicated a diagnosis of autoimmune encephalitis compatible with BBE. The lack of a clear ophthalmoplegia was probably due to the quick evolution toward disturbed status of consciousness. However, retrospectively the patient reported diplopia among the symptoms at the onset.
MRI showed T2-hyperintense-enhancing lesions in the brainstem and periventrincular regions, and also demonstrated cranial nerve enhancement, confirming both CNS and PNS involvement. Furthermore, the presence of tetraparesis, as well as the enhancement of the cauda equina, suggested an association with GBS, including our case in the subgroup of BBE associated with GBS, as reported by Odaka et al. 1 Notably, our patient presented a dramatic involvement of the spinal cord. To our knowledge, this finding has not been previously reported in the literature and may represent an additional variant of BBE, with less favorable prognosis, in the spectrum of anti-Gq1b antibody syndromes. Further studies are required to confirm these findings. 
